Best Shoulder Pain Treatments: A Sports Medicine Tier List
- 5 hours ago
- 9 min read
By Dr. Jeffrey Peng, MD · Published May 16, 2026 · 9 min read
Watch the Full Video
There is no shortage of recommendations for rotator cuff and shoulder pain — rest the shoulder, get a cortisone injection, try stem cells, get surgery, do physical therapy. But not all of these interventions are created equal, and some of the most popular options have very little evidence behind them. As a sports medicine physician practicing in the San Francisco Bay Area, I've helped thousands of patients with shoulder pain return to active and pain-free lives, and the gap between what is most often prescribed and what actually works is wider than most patients realize.
In this guide I rank the most common shoulder pain and rotator cuff treatments using a tier system. S tier represents the strongest, best-evidenced treatments. A tier covers very good options that fall just short of the top category. B tier includes solid treatments with moderate benefit. C tier is for weaker or more situational options. F tier is for treatments I recommend avoiding. This guide is intended for adults with rotator cuff syndrome — including rotator cuff tendinopathy, degenerative partial tears, and subacromial impingement syndrome — and not for acute traumatic shoulder injuries or frozen shoulder, though there is meaningful overlap in management.
F Tier: Rest and Immobilization
Rest sounds like the most natural recommendation in the world — if something hurts, stop using it. The problem is that tendons hate being immobilized. Tendons need mechanical load and stimulus to maintain their structure and to heal. In adults over 40, most rotator cuff problems are not acute injuries but rather degenerative, and that ongoing degeneration is precisely what drives muscle weakness, impingement, and pain in the first place. When you fully rest and immobilize a shoulder, you accelerate muscle atrophy on top of the existing tendon degeneration, which usually makes the underlying problem worse rather than better.
What actually helps is relative rest combined with activity modification. Lower the weights you are lifting rather than abandoning the gym. Take more frequent breaks during sports, modify your workouts, and add extra recovery days, but keep moving and keep loading the tendon. Tendons adapt to load — too much load too fast aggravates them, too little load over time weakens them. Complete rest sits at the wrong end of that spectrum. For that reason, full rest and immobilization belongs in the F tier. Structured loading, not stillness, is what rebuilds a painful shoulder.
B Tier: NSAIDs (Ibuprofen, Naproxen, and Similar)
Non-steroidal anti-inflammatory drugs — ibuprofen (Advil), naproxen (Aleve), diclofenac, celecoxib, and meloxicam, among others — work reasonably well for shoulder pain and inflammation. The catch is that this is all they do. They do not strengthen muscles, they do not rebuild tendon, and they do not correct biomechanical problems. Their real value is that they take the edge off pain enough for someone to participate in a structured rehabilitation program. Used that way, they are genuinely useful.
The reason NSAIDs land in the B tier rather than higher is that long-term use carries real risks. Chronic NSAID use is associated with stomach ulcers, gastrointestinal bleeding, kidney injury, and adverse cardiovascular events — risks that grow with age and with other medical conditions. NSAIDs are best used as a short-term, as-needed bridge to active treatment, not as a long-term solution.
C Tier: Cortisone (Corticosteroid) Injections
Cortisone injections have been used for shoulder pain for nearly seventy years. They are inexpensive, quick to administer in clinic, and often provide rapid pain relief. For someone with severe shoulder pain that is interfering with sleep and daily function, a well-placed steroid injection can be transformative in the short term.
The concern is what cortisone does to tissue over time. A cohort study of more than 1,000 patients with shoulder disease found that those who received steroid injections had a roughly 7.4-fold increase in the adjusted risk of rotator cuff tendon tears compared to those who did not. That is consistent with the broader concern that repeated steroid exposure weakens tendon tissue and accelerates the same degenerative process we are trying to treat.
In my practice, I view cortisone as a situational tool. One or two injections to break a severe pain cycle — or to get a patient through an important wedding, vacation, or competition — is reasonable. Repeated cortisone shots year after year is not, especially when better options exist. That is why cortisone sits in the C tier: useful in narrow circumstances, but no longer a default treatment.
C Tier: Stem Cell Injections
Three preparations are commonly marketed in the United States as stem cell therapy for shoulder pain: bone marrow aspirate concentrate (BMAC), which is harvested from the pelvic bone; adipose-derived stem cells, harvested from abdominal fat; and perinatal products such as umbilical cord or amniotic-derived preparations.
The trouble with calling these treatments "stem cell" injections is that the cellular content does not match the marketing. A single-cell transcriptomic analysis of paired BMAC and adipose-derived stromal vascular fraction samples from UC San Diego found that only a small fraction of the cells in either product meet the criteria for mesenchymal stem cells — challenging the notion that one therapeutic cell type is doing the heavy lifting in either preparation. A separate laboratory study examining commercial amniotic fluid products found no culturable mesenchymal stem cells at all; the few living cells that could be identified did not exhibit established stem cell characteristics.
Two things are still true. First, these preparations contain meaningful concentrations of growth factors, which is why a number of clinical trials show that they do improve outcomes — they just aren't working through the stem cell mechanism patients are usually paying for. Second, head-to-head trials suggest these treatments do not outperform platelet-rich plasma (PRP), which is far less expensive and more widely available. True cell expansion — harvesting your own cells, culturing them in a lab, and then re-injecting them — is not legal in the United States. So I cannot put these treatments in F tier, because the trial evidence shows they work to some degree, but they also are not what most patients think they are buying. Solid C tier.
F Tier: Arthroscopic Subacromial Decompression Surgery
Arthroscopic subacromial decompression — sometimes called a "cleanup" surgery — is one of the most common operations performed for shoulder pain in adults with degenerative rotator cuff tendinopathy and no full-thickness tear. It involves removing bone spurs and inflamed soft tissue around the rotator cuff. The question is whether it actually helps.
Two landmark placebo-controlled surgical trials have followed patients out to a full decade. In the UK CSAW trial, published in The Lancet at one year, arthroscopic subacromial decompression offered no clinically meaningful benefit over a sham arthroscopy in which no bone or soft tissue was actually removed. The Finnish FIMPACT trial then followed a similar three-arm comparison (decompression vs. diagnostic arthroscopy vs. exercise therapy) over the long term: at two years, no advantage of decompression over placebo surgery; at five years, still no advantage; and at ten years, no advantage. Across short, medium, and long-term follow-up, the surgery does not outperform a placebo procedure or exercise therapy.
Given the consistent absence of benefit and the very real risks and recovery time of any shoulder operation, arthroscopic subacromial decompression for this indication is an F tier treatment. The evidence has been clear for years, and now we have a decade of follow-up confirming it.
B Tier: Shockwave Therapy
A quick terminology note: most physical therapy and chiropractic clinics offer a radial pressure wave device, which is technically distinct from a focused extracorporeal shockwave device. In rigorous physics terms, only the focused device produces a true shockwave; radial pressure wave units produce a different acoustic profile. In clinical practice, the distinction matters less than the marketing implies. A systematic review and meta-analysis found that extracorporeal shockwave therapy produces small but real short-term improvements in pain in noncalcific rotator cuff tendinopathy, and focused shockwave tends to outperform radial in more difficult cases such as calcific tendinitis.
The appeal of shockwave therapy is that it has essentially no side effects, no downtime, and no post-treatment restrictions. A typical course runs once a week for three to five weeks. The main downside is cost — most insurance plans do not cover it. In my practice, patients with chronic rotator cuff pain who add shockwave to an exercise program or to PRP tend to do measurably better than those doing rehabilitation alone. That places shockwave squarely in the B tier: meaningful benefit, very low risk, but not the strongest single intervention available.
A Tier: Platelet-Rich Plasma (PRP) Injections
The use of platelet-rich plasma for shoulder pain has expanded enormously over the past decade, and the results I have seen across several thousand of these injections — for rotator cuff tendinopathy, partial-thickness rotator cuff tears, calcific tendinitis, subacromial impingement, and shoulder arthritis — have been consistently strong. The clinical trial evidence has caught up with what I see in practice.
A randomized, double-blind clinical trial from Brazil enrolled patients with high-grade partial supraspinatus tendon tears and randomized them to ultrasound-guided barbotage with PRP versus barbotage with saline. At six months, nearly 80 percent of patients in the PRP arm showed complete tendon healing on ultrasound, compared to a much lower rate in the saline group. The PRP group also had better pain scores and better functional outcomes. This is the kind of result that historically required surgery to achieve, and it can now be obtained with a single in-office injection.
The main limitation of PRP is cost — most insurance plans do not cover it, even though it is arguably one of the highest-value treatments we can offer for shoulder pain. PRP earns a strong A tier rating. If insurance routinely covered it, it would easily be an S tier treatment.
S Tier: Structured Rehabilitation and Physical Therapy
The most important — and most under-emphasized — finding in modern rotator cuff research has nothing to do with injections or surgery. A recent population-based MRI study examined more than 1,200 shoulder MRIs in 602 adults aged 41 to 76 and asked a simple question: how common are rotator cuff abnormalities as people age? The answer was that roughly 99 percent of adults had at least one rotator cuff abnormality on MRI, and even in shoulders that were completely pain-free, 96 percent still showed an abnormality.
This finding reframes how we should think about a painful shoulder. Rotator cuff abnormalities are nearly universal after the age of 40, yet most people walking around with them are asymptomatic. When a patient becomes symptomatic, the MRI finding usually is not the whole explanation. The real driver, in most cases, is biomechanics — a muscle imbalance where the rotator cuff and scapular stabilizers are not doing their job, which leads to impingement and pain on top of an underlying structural finding that may have been present, silently, for years.
That is the entire foundation for structured rehabilitation. The goal is not to chase the imaging finding. The goal is to fix the mechanics: strengthen the rotator cuff and scapular stabilizers, restore range of motion, and retrain movement patterns. When the mechanics are corrected, most of the imaging abnormalities stop being clinically relevant. Shoulder rehabilitation exercises are inexpensive, broadly accessible, and work remarkably well when done consistently. That is an easy S tier ranking — and it is the foundation on which every other treatment in this guide should be built.
The Bottom Line: Where to Start with Shoulder Pain
Almost every patient with rotator cuff syndrome should start with a structured rehabilitation program. Layer in shockwave or PRP for patients who plateau or who present with more advanced tendinopathy or partial tears. Use NSAIDs as a short-term bridge, and reserve cortisone for situational pain control rather than chronic management. Skip arthroscopic subacromial decompression for non-traumatic, no-full-thickness-tear shoulder pain, and recognize that current commercial "stem cell" products do not deliver what most patients believe they are paying for.
If you are dealing with persistent shoulder or rotator cuff pain and want to discuss whether PRP, shockwave, or another non-surgical option makes sense in your case, you can schedule a consultation here. Additional shoulder articles are available on the shoulder blog page.
References
1. Lin CY, Huang SC, Tzou SJ, et al. A positive correlation between steroid injections and cuff tendon tears: a cohort study using a clinical database. Int J Environ Res Public Health. 2022;19(8):4520. doi:10.3390/ijerph19084520.
2. Ruoss S, Nasamran CA, Ball ST, et al. Comparative single-cell transcriptional and proteomic atlas of clinical-grade injectable mesenchymal source tissues. Sci Adv. 2024;10(28):eadn2831. doi:10.1126/sciadv.adn2831.
3. Panero AJ, Hirahara AM, Andersen WJ, Rothenberg J, Fierro F. Are amniotic fluid products stem cell therapies? A study of amniotic fluid preparations for mesenchymal stem cells with bone marrow comparison. Am J Sports Med. 2019;47(5):1230–1235. doi:10.1177/0363546519829034.
4. Beard DJ, Rees JL, Cook JA, et al. Arthroscopic subacromial decompression for subacromial shoulder pain (CSAW): a multicentre, pragmatic, parallel group, placebo-controlled, three-group, randomised surgical trial. Lancet. 2018;391(10118):329–338. doi:10.1016/S0140-6736(17)32457-1.
5. Paavola M, Malmivaara A, Taimela S, et al. Subacromial decompression versus diagnostic arthroscopy for shoulder impingement: randomised, placebo surgery controlled clinical trial. BMJ. 2018;362:k2860. doi:10.1136/bmj.k2860.
6. Paavola M, Kanto K, Ranstam J, et al. Subacromial decompression versus diagnostic arthroscopy for shoulder impingement: a 5-year follow-up of a randomised, placebo surgery controlled clinical trial. Br J Sports Med. 2021;55(2):99–107. doi:10.1136/bjsports-2020-102216.
7. Kanto K, Bäck M, Ibounig T, et al. Arthroscopic subacromial decompression versus placebo surgery for subacromial pain syndrome: 10 year follow-up of the FIMPACT randomised, placebo surgery controlled trial. BMJ. 2025;391:e086201. doi:10.1136/bmj-2025-086201.
8. Kamonseki DH, da Rocha GM, Ferreira VMLM, Ocarino JM, Pogetti LS. Extracorporeal shockwave therapy for the treatment of noncalcific rotator cuff tendinopathy: a systematic review and meta-analysis. Am J Phys Med Rehabil. 2024;103(6):471–479. doi:10.1097/PHM.0000000000002361.
9. de Castro RLB, Antonio BP, Giovannetti GA, Annichino-Bizzacchi JM. Total healing of a partial rupture of the supraspinatus tendon using barbotage technique associated with platelet-rich plasma: a randomized, controlled, and double-blind clinical trial. Biomedicines. 2023;11(7):1849. doi:10.3390/biomedicines11071849.
10. Ibounig T, Järvinen TLN, Raatikainen S, et al. Incidental rotator cuff abnormalities on magnetic resonance imaging. JAMA Intern Med. 2026;186(4):406–414. doi:10.1001/jamainternmed.2025.7903.
Medical Disclaimer: This content is for educational purposes only and does not substitute for the medical advice of a physician. Always consult your healthcare provider before beginning any new treatment program. The information presented reflects the opinion of Dr. Jeffrey Peng and does not represent the views of his employers or affiliated hospital systems.
Comments